

**QP Code: 830006**

**Reg. No.....**

**Eighth Semester B. Pharm Degree Supplementary Examinations  
November 2024  
Experimental Pharmacology  
(2017 Scheme)**

**Time: 3 Hours**

**Max. Marks: 75**

- *Answer all questions to the point neatly and legibly • Do not leave any blank pages between answers • Indicate the question number correctly for the answer in the margin space*
- *Answer all parts of a single question together • Leave sufficient space between answers*
- *Draw diagrams wherever necessary*

**Essays**

**(2x10=20)**

1. (a) Write the functions of CPCSEA  
(b) Write a brief note about collection of blood and route of drug administration in laboratory animals.
2. List the anti-inflammatory and anti-psychotic screening models and explain any one screening model in each.

**Short Notes**

**(7x5=35)**

3. How do you differentiate Wistar and Sprague Dawley (SD) rats. Write their experimental uses.
4. Screening methods for anticancer activity. Explain.
5. List the various in-vivo and in-vitro screening models for anti-ulcer and explain any one of them.
6. Rationale behind the selection of animal species. Differentiate sham negative and sham positive control in pre-clinical screening models.
7. Review of literature.
8. Explain one-way ANOVA with an example.
9. Explain about observational study design.

**Answer Briefly**

**(10x2=20)**

10. Define anaesthesia and euthanasia.
11. Enlist the types of breeding in experimental animals.
12. Enlist the screening model for nootropics.
13. Define transgenic animals. Mention their applications.
14. List out animal models for screening of antihypertensive activity.
15. Explain the concept of 3Rs in preclinical studies.
16. Mention different equipment used to assess diuretic activity.
17. Screening methods for anti-dyslipidemic drugs.
18. What are ex-vivo studies. Give an example.
19. Interpretation of student's t-test.

\*\*\*\*\*